|
Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer. |
|
Marie Lena Johanna Tzschaschel |
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca; Chugai Pharma; Janssen; Lilly; Novartis; Sanofi |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Novartis; Sanofi |
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Novartis; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Novartis; Roche |
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; PharmaMar; Roche |
Research Funding - Novartis |
|
|
|
Research Funding - Veridex |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Elisabeth Katharina Trapp |
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; GlaxoSmithKline; Janssen-Cilag; Jenapharm; Medac; PharmaMar; Roche/Genentech; Teva |
Consulting or Advisory Role - AstraZeneca; Janssen-Cilag; Medac; Merck Sharp & Dohme; Roche; Tesaro |
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Janssen-Cilag; Medac; PharmaMar; Roche; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis; Sanofi |
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Novartis; Sanofi |
|
|
Honoraria - Amgen; GlaxoSmithKline; Novartis; Pfizer; Roche; Teva |
Consulting or Advisory Role - Novartis; Pfizer; Roche; Teva |
Speakers' Bureau - Amgen; GlaxoSmithKline; Novartis; Pfizer; Roche; Teva |
Research Funding - Amgen (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
Honoraria - Janssen Diagnostics |
Consulting or Advisory Role - Janssen Diagnostics |
Research Funding - Janssen Diagnostics |